We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
+8.53%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$363M
AUM Growth
+$13.2M
(+3.8%)
Cap. Flow
+$3.91M
Cap. Flow
% of AUM
1.08%
Top 10 Holdings %
Top 10 Hldgs %
35.6%
Holding
94
New
25
Increased
21
Reduced
19
Closed
23
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$13.4M |
| 2 |
Biogen
BIIB
|
+$10.6M |
| 3 |
Universal Health Services
UHS
|
+$9.83M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$9.37M |
| 5 |
Sanofi
SNY
|
+$9.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intellia Therapeutics
NTLA
|
+$10.9M |
| 2 |
Charles River Laboratories
CRL
|
+$10.1M |
| 3 |
McKesson
MCK
|
+$9.75M |
| 4 |
Centene
CNC
|
+$9.59M |
| 5 |
Envista
NVST
|
+$7.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.34% |
| 2 | Energy | 2.32% |
| 3 | Industrials | 1.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Elevance Health
ELV
$81.5B
| $19.1M | 5.26% |
50,000
+35,000
| +233% | +$13.4M |
|
2
Acadia Healthcare
ACHC
$2.76B
| $16.3M | 4.49% |
260,000
-85,000
| -25% | -$5.33M |
|
|
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $15.3M | 4.22% |
225,000
+15,000
| +7% | +$978K |
|
4
Cytokinetics
CYTK
$10.5B
| $13.9M | 3.81% |
700,000
| – | – |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $12.7M | 3.5% |
224,000
+80,000
| +56% | +$5.66M |
|
|
6
Biogen
BIIB
$30B
| $12.1M | 3.34% |
+35,000
| New | +$10.6M |
|
|
7
Regeneron Pharmaceuticals
REGN
$78.5B
| $10.3M | 2.84% |
+18,500
| New | +$9.37M |
|
8
Globus Medical
GMED
$10.7B
| $10.1M | 2.77% |
130,000
+55,000
| +73% | +$3.91M |
|
9
Medtronic
MDT
$109B
| $9.93M | 2.73% |
80,000
+30,000
| +60% | +$3.77M |
|
|
10
Universal Health Services
UHS
$10.2B
| $9.52M | 2.62% |
+65,000
| New | +$9.83M |
|
|
11
Sanofi
SNY
$103B
| $9.22M | 2.54% |
+175,000
| New | +$9.13M |
|
|
BPMC
12
DELISTED
Blueprint Medicines
BPMC
| $8.8M | 2.42% |
100,000
-17,500
| -15% | -$1.6M |
|
|
LHCG
13
DELISTED
LHC Group LLC
LHCG
| $8.41M | 2.32% |
42,000
-13,000
| -24% | -$2.61M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.08M | 2.22% |
50,000
| – | – |
|
15
Teleflex
TFX
$6.05B
| $8.04M | 2.21% |
20,000
+8,000
| +67% | +$3.28M |
|
16
Cencora
COR
$60.6B
| $8.01M | 2.21% |
+70,000
| New | +$8.27M |
|
|
17
Envista
NVST
$4.44B
| $7.78M | 2.14% |
180,000
-165,000
| -48% | -$7.16M |
|
18
Fate Therapeutics
FATE
$286M
| $6.94M | 1.91% |
80,000
+40,000
| +100% | +$3.22M |
|
19
Edwards Lifesciences
EW
$49.6B
| $6.73M | 1.85% |
+65,000
| New | +$6.13M |
|
20
Zentalis Pharmaceuticals
ZNTL
$337M
| $6.65M | 1.83% |
125,000
+85,000
| +213% | +$4.55M |
|
|
AERI
21
DELISTED
Aerie Pharmaceuticals
AERI
| $6.56M | 1.81% |
410,000
+60,000
| +17% | +$1.03M |
|
22
Denali Therapeutics
DNLI
$3.65B
| $6.35M | 1.75% |
81,000
-16,000
| -16% | -$990K |
|
|
NVRO
23
DELISTED
NEVRO CORP.
NVRO
| $6.3M | 1.73% |
38,000
-2,000
| -5% | -$312K |
|
24
Natera
NTRA
$38.3B
| $6.24M | 1.72% |
55,000
+20,000
| +57% | +$2.05M |
|
25
Revvity
RVTY
$12.6B
| $6.18M | 1.7% |
40,000
-10,000
| -20% | -$1.41M |
|
Similar funds
CL
ACM
NSCM
ACG
NSUP
TP
ACP
TA
Integral Health Asset Management's Q2 2021 Portfolio in Review
As of Q2 2021, Integral Health Asset Management held 94 positions worth $363M, up 3.8% from $350M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Integral Health Asset Management's Q2 2021 filing shows 25 new, 21 increased, 19 reduced and 23 closed positions. Its largest new stake was Biogen: 35,000 shares worth $12.1M. The largest sale was Intellia Therapeutics, an estimated $10.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Energy and Industrials.
- Integral Health Asset Management's largest Q2 2021 buy was Biogen: 35,000 shares worth $12.1M.
- Integral Health Asset Management added most to Elevance Health in Q2 2021, an estimated $13.4M increase.
- Integral Health Asset Management's biggest Q2 2021 reduction was Intellia Therapeutics, cutting an estimated $10.9M.
- Integral Health Asset Management fully exited Charles River Laboratories in Q2 2021, selling an estimated $10.1M.
- Integral Health Asset Management's ten largest holdings make up 36% of its $363M portfolio in Q2 2021.
- Integral Health Asset Management opened 25 new positions and closed 23 in Q2 2021.
- Integral Health Asset Management's portfolio value rose 3.8% quarter-over-quarter to $363M.
Based on Integral Health Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.